Gentamicin PDF

Preview

Summary

GENTAMICIN...

Description

A Drug Study On GENTAMICIN INTRAMASCULAR

In Partial Fulfillment of the Requirements in NCM- 209 RLE

Submitted to: Claudette Advindicula, RN, MN Clinical Instructor

Submitted by: Janiel Kayyi D. Torralba, St N. BSN-2E- GROUP 2

January 28, 2021

GENTAMICIN INTRAMASCULAR

i.

Generic Name: Gentamicin

ii.

Brand Name 

iii.

Servigenta (FDA Philippines)

Classification

a. PHARMACOTHERAPEUTIC Aminoglycoside



b. CLINICAL Antibiotic

 iv.

Ordered Dose And Frequency  Usual Parenteral Dosage IM, IV: ADULTS, ELDERLY: (Conventional): 3–5 mg/kg/day in divided



doses q8h. (Once Daily): 5–7 mg/kg/dose q24h. 

CHILDREN 5 YRS AND OLDER: 2–2.5 mg/kg/dose q8h.



INFANTS, CHILDREN YOUNGER THAN 5 YRS: 2.5 mg/kg/dose q8h.



NEONATES

(GREATER

THAN

2

KG)PNA

8–28

days:

4–5

mg/kg/dose q24h; PNA 7 days or less: 4 mg/kg/dose q24h. (1–2 KG)PNA 8–28 days: 5 mg/kg/dose q36h; PNA 7 days or less: 5 mg/kg/dose q48h. 

(LESS THAN 1 KG)PNA 15–28 days: 5 mg/kg/dose q36h; PNA 14 days or less: 5 mg/kg/dose q48h.

 v.

Suggested Dose (By Manufacturer)  Injectable solution

vi.



10 mg/ml (Pediatric)



40 mg/ml

Mode of Action Indication



Irreversibly binds to protein of bacterial ribosomes. Therapeutic Effect: Interferes with protein synthesis of susceptible microorganisms.



Gentamicin is bactericidal and acts by inhibiting protein synthesis in susceptible bacteria, which results in cell death.

vii.

Contraindications

 

Known hypersensitivity to gentamicin or disodium edetate or Patients who have experienced previous toxic reactions (ototoxicity, nephrotoxicity) resulting from aminoglycoside therapy.



Avoid potent diuretics because they increased risk of ototoxicity; when administered

intravenously,

aminoglycoside toxicity by

diuretics

may

altering antibiotic concentrations

enhance in

serum

and tissue.

viii.

Drug interaction 

DRUG: Nephrotoxic (e.g., lisinopril, IV contrast dye), ototoxic medications (e.g., CISplatin, furosemide) may increase risk of nephrotoxicity, ototoxicity. May increase neuromuscular blockade with concurrent use of neuromuscular blockers (e.g., succinylcholine).



FOOD: None known.



LAB VALUES: May increase serum BUN, creatinine, bilirubin, LDH, ALT, AST. May decrease serum calcium, magnesium, potassium, sodium.



Therapeutic serum level: peak: 4–10 mcg/mL; trough: 0.5–2 mcg/mL.



Toxic serum level: peak: greater than 10 mcg/mL; trough: greater than 2 mcg/mL.

ix.

Side effects...